Jan 16 (Reuters) - Cellect Biotechnology Ltd:
* CELLECT ANNOUNCES OPENING OF A SECOND CLINICAL TRIAL SITE AND APPROVAL FROM SAFETY BOARD (DSMB) FOR DOSE ESCALATION
* CELLECT BIOTECHNOLOGY - SIGNED AGREEMENT WITH HADASSAH MEDICAL CENTER TO CONDUCT CLINICAL TRIALS ON CANCER PATIENTS IN CO'S ONGOING PHASE I/II STUDY
* CELLECT BIOTECHNOLOGY - GOT APPROVAL FROM DSMB TO ESCALATE APOGRAFT FASL PROTEIN DOSAGE TO 25 NG/ML, ENROLL 3 ADDITIONAL PATIENTS FOR CLINICAL TRIAL Source text for Eikon: Further company coverage: